LY3009120

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Ono Pharma

Drug class:

pan-RAF inhibitor

Related drugs:

BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
GATA2 mutation	Acute Myelogenous Leukemia	GATA2 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sorafenib + LY3009120 Sensitive: D – Preclinical sorafenib + LY3009120 Sensitive : D	sorafenib + LY3009120 Sensitive: D – Preclinical sorafenib + LY3009120 Sensitive : D
TARDBP-BRAF fusion	Melanoma	TARDBP-BRAF fusion	Melanoma	trametinib + LY3009120 Sensitive: D – Preclinical trametinib + LY3009120 Sensitive : D	trametinib + LY3009120 Sensitive: D – Preclinical trametinib + LY3009120 Sensitive : D
BRAF L485-P490 deletion	Ovarian Serous Adenocarcinoma	BRAF L485-P490 deletion	Ovarian Serous Adenocarcinoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
BRAF L485-P490 deletion	Non Small Cell Lung Cancer	BRAF L485-P490 deletion	Non Small Cell Lung Cancer	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
BRAF L485-P490 deletion	Pancreatic Cancer	BRAF L485-P490 deletion	Pancreatic Cancer	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	cetuximab + LY3009120 Sensitive: D – Preclinical cetuximab + LY3009120 Sensitive : D	cetuximab + LY3009120 Sensitive: D – Preclinical cetuximab + LY3009120 Sensitive : D
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D	LY3009120 Sensitive: D – Preclinical LY3009120 Sensitive : D
EGFR E746_A750del + KRAS amplification	Non Small Cell Lung Cancer	EGFR E746_A750del + KRAS amplification	Non Small Cell Lung Cancer	osimertinib + LY3009120 Sensitive: D – Preclinical osimertinib + LY3009120 Sensitive : D	osimertinib + LY3009120 Sensitive: D – Preclinical osimertinib + LY3009120 Sensitive : D

LY3009120

Associations
(22)

Associations
(22)

LY3009120

Associations(22)

Associations(22)

Associations
(22)

Associations
(22)